Catalyst Pharmaceuticals ...

22.52
0.33 (1.49%)
At close: Apr 17, 2025, 3:59 PM
22.40
-0.53%
After-hours: Apr 17, 2025, 07:53 PM EDT
1.49%
Bid 22.4
Market Cap 2.74B
Revenue (ttm) 491.73M
Net Income (ttm) 163.89M
EPS (ttm) 1.31
PE Ratio (ttm) 17.19
Forward PE 13.39
Analyst Buy
Ask 22.98
Volume 691,861
Avg. Volume (20D) 1,276,627
Open 22.31
Previous Close 22.19
Day's Range 22.19 - 22.64
52-Week Range 14.47 - 26.16
Beta 0.79

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2006
Employees 181
Stock Exchange NASDAQ
Ticker Symbol CPRX
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 42.10% from the latest price.

Stock Forecasts

Next Earnings Release

Catalyst Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-1.88%
Catalyst Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
1 month ago
+5.25%
Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.